Equities

Japan Tissue Engineering Co Ltd

7774:TYO

Japan Tissue Engineering Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (JPY)670.00
  • Today's Change9.00 / 1.36%
  • Shares traded21.80k
  • 1 Year change+29.34%
  • Beta1.1313
Data delayed at least 20 minutes, as of Apr 18 2024 02:45 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Japan Tissue Engineering Co Ltd is a Japan-based company mainly engaged in regenerative medicine product business, regenerative medicine outsourcing business, and research and development support business. The Company operates through three segments. The Regenerative Medicine Product segment develops regenerative medicine products using tissue engineering, and manufactures and sells the products for medical institutions. The regenerative medicine products include autologous cultured epidermis JACE, and autologous cultured cartilage JACK. The Regenerative Medicine Outsourcing segment provides contract development and manufacturing organization (CDMO) services, contract research organization (CRO) services, consulting services, and contract manufacturing services for specific cell processed products. The Research and Development Support segment manufactures and sells human cultured tissues that apply advanced culture technology accumulated through the development of in-house products.

  • Revenue in JPY (TTM)2.37bn
  • Net income in JPY-157.25m
  • Incorporated1999
  • Employees215.00
  • Location
    Japan Tissue Engineering Co Ltd6-209-1, Miyakita-doriGAMAGORI-SHI 443-0022JapanJPN
  • Phone+81 533662020
  • Fax+81 533662019
  • Websitehttps://www.jpte.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Techno Medica Co Ltd9.73bn1.23bn15.17bn225.0011.560.913411.281.56149.84149.841,190.251,896.310.58222.413.6343,247,240.007.386.598.357.6449.9248.1612.6712.035.27--0.0039.88-3.421.60-10.20-2.5418.515.92
Medius Holdings Co Ltd247.46bn1.14bn16.73bn2.29k14.690.89925.900.067651.9451.9411,254.21848.562.3317.024.37108,156,900.001.081.644.416.0212.1311.490.46220.58370.896268.940.589931.155.497.29-19.8015.0942.529.46
HOSHI IRYO-SANKI CO., LTD14.59bn1.38bn16.83bn470.0011.140.93167.301.15441.64441.644,683.445,281.520.686823.495.7631,036,470.006.535.438.216.8948.6749.229.508.332.83--0.0017.697.895.7213.237.7710.738.45
Japan Medical Dynamic Marketing, INC.22.68bn1.02bn17.66bn488.0017.250.72346.760.778738.6738.67861.74922.000.77190.66524.1946,469,640.003.557.494.018.8664.2768.464.6010.262.13--0.073815.5311.027.55-33.34-0.02455.2810.20
Daiken Medical Co Ltd9.65bn912.09m17.86bn188.0017.672.3315.891.8531.7531.75335.80240.850.87443.723.5951,314,050.008.277.1812.1210.4739.0542.969.459.251.52509.690.267673.266.991.25-14.32-6.79-20.77-0.9711
Seed Co Ltd32.05bn648.96m18.07bn974.0023.031.165.400.563825.9225.921,280.20514.910.7562.447.7632,903,220.001.431.572.542.7942.5542.591.892.120.613226.090.632447.176.101.91-127.39---34.239.86
Japan Tissue Engineering Co., Ltd.2.37bn-157.25m26.36bn215.00--4.48--11.10-3.87-3.8758.47144.880.34473.525.2911,044,030.00-2.28-5.66-2.62-6.3164.0254.44-6.62-20.925.30--0.00---3.38-2.20-46.48--40.63--
Cyberdyne Inc4.13bn-1.32bn27.49bn257.00--1.02--6.65-6.22-6.2219.52195.180.08141.949.0416,081,710.00-2.90-0.7423-2.95-0.754449.6065.33-35.62-16.4417.29--0.015--52.9813.7440.16---14.67--
Nippon Care Supply Co., Ltd.27.74bn1.50bn31.25bn1.25k19.871.854.211.1396.2596.251,785.431,032.501.20125.2123.4422,122,560.006.447.878.6910.1936.1338.345.397.350.7474--0.093653.1111.149.66-9.601.2036.008.76
Win-Partners Co Ltd74.40bn1.69bn36.02bn609.0019.851.4918.920.484259.5159.512,613.33795.081.7221.314.38122,162,200.003.934.967.139.1712.3312.502.282.981.75--0.0052.936.722.4311.76-7.3937.315.92
Rion Co Ltd25.40bn2.51bn37.05bn998.0014.721.3211.071.46204.08204.082,064.162,283.730.73231.783.8825,449,890.007.246.168.297.1250.7750.829.898.612.57--0.0028.075.443.24-19.28-0.952520.315.15
CI Medical Co Ltd45.63bn2.08bn39.50bn473.0018.971.9712.650.8657208.22208.224,563.262,005.931.274.2514.4796,465,120.005.8610.8310.7015.6526.2927.734.606.060.4438--0.460512.836.3812.07-17.419.3877.2413.65
Data as of Apr 18 2024. Currency figures normalised to Japan Tissue Engineering Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

0.17%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 04 Apr 202461.70k0.15%
Sawakami Asset Management, Inc.as of 31 Jan 20246.20k0.02%
Mitsubishi UFJ Asset Management Co., Ltd.as of 16 Sep 20220.000.00%
Data from 31 Dec 2023 - 11 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.